Mustang Bio, Inc. (NASDAQ:MBIO) Sees Significant Increase in Short Interest

Mustang Bio, Inc. (NASDAQ:MBIO) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 150,627 shares, a growth of 176.0% from the May 31st total of 54,570 shares. Based on an average daily volume of 553,998 shares, the short-interest ratio is presently 0.3 days. Currently, 2.1% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of Mustang Bio

A hedge fund recently bought a new position in Mustang Bio stock. DRW Securities LLC acquired a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned approximately 1.01% of Mustang Bio as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Mustang Bio Stock Performance

Shares of Mustang Bio stock traded down $0.03 on Tuesday, reaching $0.67. The company had a trading volume of 10,796 shares, compared to its average volume of 153,030. The firm’s 50 day moving average price is $0.70 and its two-hundred day moving average price is $0.86. The firm has a market cap of $5.08 million, a PE ratio of -1.40 and a beta of 2.08. Mustang Bio has a 52-week low of $0.53 and a 52-week high of $7.00.

Mustang Bio (NASDAQ:MBIO) last posted its earnings results on Tuesday, May 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($140.00) by $139.86.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.